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NONO, the non-octamer-containing, POU-domain DNA-binding 
protein, also known as p54NRB, belongs to the highly conserved 
Drosophila behavior/human splicing (DBHS) protein family. This 
family includes three members in mammals: NONO, paraspeckle 
component 1 (PSPC1) and splicing factor proline/glutamine-rich 
(SFPQ, also known as PSF). DBHS proteins are nuclear proteins 
forming homo- and heterodimers in vivo1,2, and previous literature 
documents their involvement in various aspects of RNA metabo-
lism3. Studies in vitro suggest that they act in transcriptional activa-
tion and repression4–6, splicing7,8, pre-mRNA processing9 and RNA 
transport10,11. In addition, they are major components of nuclear 
paraspeckles, which have been recognized as nuclear RNA-holding 
structures for edited RNAs12,13 that likely function in stress-mediated 
regulation via nuclear retention of transcripts14–16. NONO and other 
DBHS family members also serve as transcriptional cofactors for cor-
rect circadian clock function in both flies and mammals, where they 
regulate the circadian clock via interaction with PER proteins17–20. 
However, no study so far has linked impaired function of these 
proteins to human disease. Here we demonstrate that the NONO 
protein extensively regulates synaptic transcript abundance and 
that its mutation or deletion results in impaired cognitive function 
in both humans and mice.
Human intellectual disability is characterized by limitations in 
intellectual functioning and adaptive behavior. Recent developments 
in next-generation sequencing and whole-exome sequencing have 
empowered detection of disease variants in intellectual disability21–23. 
Through these strategies, many new genes have been identified. By 
contrast, identifying the underlying pathophysiological mechanisms 
has remained a considerable challenge. Besides the molecular charac-
terization of a novel clinically recognizable intellectual disability condi-
tion, our study has been empowered by the analysis of NONO-deficient 
mice, which share both transcriptional and morphological characteris-
tics with patients. Our data suggest that NONO may contribute to the 
regulation of RNA metabolism underlying local regulation of dendritic 
spine morphology and that it has a major and unsuspected role in 
regulating synaptic morphology at a cellular level.
RESULTS
Mutations in human NONO are a likely cause of intellectual 
disability
Whole-exome sequencing was carried out in parallel in two unrelated 
male intellectual disability patients (MCCID1 and MCCID2), who pre-
sented the same gestalt of slender build, macrocephaly, distinctive facial 
features, shy behavior, a thick corpus callosum and a small cerebellum 
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Mutations in NONO lead to syndromic intellectual 
disability and inhibitory synaptic defects
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Steven J Moss13, Jean-Marc Fritschy2, Arnold Munnich3, Jeanne Amiel3,4, Steven A Brown1,15, Shiva K Tyagarajan2,15 &  
Laurence Colleaux3,15
The NONO protein has been characterized as an important transcriptional regulator in diverse cellular contexts. Here we show 
that loss of NONO function is a likely cause of human intellectual disability and that NONO-deficient mice have cognitive and 
affective deficits. Correspondingly, we find specific defects at inhibitory synapses, where NONO regulates synaptic transcription 
and gephyrin scaffold structure. Our data identify NONO as a possible neurodevelopmental disease gene and highlight the key 
role of the DBHS protein family in functional organization of GABAergic synapses.
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(Fig. 1a,b and Supplementary Table 1 and 
Online Methods). Supposing that the same 
disease gene was shared by the two patients, 
only the X-linked NONO gene emerged as a 
candidate (Supplementary Table 2). Capillary 
sequencing confirmed the de novo occurrence 
of a splice site variant affecting the last base of 
exon 10 in patient MCCID1 (NM_001145408.1:c.1131G>A; Ala377Ala) 
(Supplementary Fig. 1). The variant identified in patient MCCID2 was 
a one-base-pair insertion in the last coding exon (NM_001145408.1:
c.1394dup; Asn466Lysfs*13) inherited from his healthy mother 
(Supplementary Fig. 1). The role of NONO mutations in the etiology 
of intellectual disability was further supported by the identification of a 
third patient from a separate cohort, in the Deciphering Developmental 
Disorders (DDD) study24. This patient carried a nonsense mutation 
in exon 10 (NM_001145408.1:c.1093C>T; p.Arg365*) and had similar 
morphological and behavioral characteristics to the other two patients 
(Supplementary Fig. 2 and Supplementary Table 1).
Immunoblot analyses of cultured skin fibroblast lysates using an 
anti-NONO polyclonal antibody showed little or no NONO protein 
in MCCID1 and MCCID2 patient cells, unlike in controls (Fig. 1c,d). 
These results were confirmed by immunocytochemistry using the 
same antibody (Fig. 1e), as well as by immunoblot with another poly-
clonal antibody (Supplementary Fig. 3).
Altered gene expression in cells from patients and Nonogt mice
Microarray analysis of cultured skin fibroblast RNAs in patients compared 
to controls revealed a marked modification in the global pattern of gene 
expression between the two groups. Indeed, hierarchical clustering ana-
lysis showed that the patient group formed an independent cluster away 
from the control RNAs (Fig. 2a). A total of 389 differentially expressed 
genes were shared by the two patients, with 372 transcripts being 
similarly affected (213 downregulated and 159 upregulated), whereas 
only 17 transcripts were deregulated in opposite directions (Fig. 2b  
and Supplementary Table 3). Notably, increased transcript levels of the 
other DBHS family members, PSPC1 (2.22 and 2.78 fold respectively) 
and SFPQ (1.54- and 1.71-fold, respectively), were detected in both 
patients compared to controls. These expression data were confirmed 
by western blot analysis showing increased amounts of PSPC1 and SFPQ 
proteins in patient fibroblasts compared to controls (Fig. 1c,d).
To further characterize the physiological role of NONO, we 
analyzed a mouse model in which the Nono gene had been disrupted 
by gene trap (gt)20. Gene expression analysis in adult dermal fibro-
blasts from wild-type and Nonogt mice revealed global transcriptional 
deregulation in the mutant mice compared to controls in patterns 
similar to those of human patients and controls. When human and 
mouse data sets were merged and submitted to a hierarchical cluster-
ing with the Spearman correlation similarity measure, the samples 
were split in two main groups. Nonogt mice samples segregated with 
the patient group, whereas wild-type mouse samples segregated 
with the human control samples (Fig. 2c). Moreover, consistent with 
the role for the NONO protein in the circadian clock established in 
mouse fibroblasts and in mice themselves20, cultured skin fibroblasts 
from patients showed a reduced amplitude of circadian oscillations 
(Supplementary Fig. 4). Taken together, these data demonstrated 
a regulatory role of NONO conserved through evolution and sup-
ported the relevance of the Nonogt model for further elucidation of 
the disease mechanism in patients.
Phenotypic comparison of patients and Nonogt mice
Visual inspection and CT scan revealed that Nonogt mice displayed a 
flattened nose, mimicking the facial anomalies observed in the patients 
(Fig. 3a–c and Supplementary Table 4). Similarly, a smaller cerebel-
lum was observed in mutant mice (Fig. 3d, Supplementary Fig. 5 and 
Supplementary Table 4) and patients (Fig. 1b and Supplementary Table 1), 
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Figure 1 NONO mutations and their functional 
consequences. (a) Photographs and pedigree 
of both patients. Filled symbols indicate the 
affected individuals. (b) Sagittal T1 and axial 
FSE T2 brain MRI of patient MCCID1 at 9 years  
old (left) and MCCID2 at 8 years old (right) 
showing a thick corpus callosum, small 
cerebellum and Chiari I malformation (arrows). 
(c) Immunoblots showing an absence of the 
NONO protein and overexpression of PSPC1 
and SFPQ proteins in patients’ cells compared 
to controls (C1 and C2). (d) Quantification of 
DBHS protein levels relative to the amount 
of total proteins, expressed as percentage 
of control values. Box plot derived from two 
independent experiments with two technical 
replicates; whiskers show minimum and 
maximum values; center line represents median; 
and box limits represent interquartile range. 
Significance was calculated using two-way 
analysis of variance (ANOVA) test with Sidak 
correction and P = 0.008268 for NONO, 0 for 
SFPQ and 0 for PSPC1. Here and in subsequent 
figures, *P < 0.05, **P < 0.01, ***P < 0.001,  
****P < 0.0001. (e) Immunofluorescence 
showing the absence of the NONO protein in 
patients’ cells and presence in controls. Scale 
bar represents 50 µm.
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as well as other structural anomalies (Supplementary Tables 1 and 4). 
Behaviorally, mice showed impaired performance in the Morris water 
maze, a test of spatial memory (Fig. 3e,f), as well as a marked anxiety 
phenotype documented via prepulse inhibition, and increased risk aver-
sion in an open field and light-dark test (Supplementary Fig. 6).
NONO regulates the abundance of synaptic RNAs
Immunofluorescence analysis using anti-NONO antibodies detected 
strong immunoreactivity in mouse brain, including cortex and 
hippocampus (Fig. 4a). Staining was strongest in neuronal (NeuN-
positive) nuclei in CA1 and CA3 pyramidal regions and granule 
cells of the dentate gyrus, but absent from neighboring astrocytes 
(GFAP-positive) (Supplementary Fig. 7). Gene expression analysis 
in hippocampi of wild-type and Nonogt mice identified 882 differ-
entially expressed genes (Fig. 4b) (GEO accession code GSE62571), 
including the two other DBHS family members, Sfpq and Pspc1, 
that were upregulated in NONO-deficient patient fibroblasts 
(Supplementary Fig. 8). Protein levels of these orthologs were 
also upregulated in Nonogt hippocampi (Supplementary Fig. 9). 
Notably, mRNA levels of Gabra2, the GABAA receptor (GABAAR) α2 
subunit, were markedly reduced in hippocampi of Nonogt mice compared 
to controls, a result confirmed by quantitative real-time PCR 
and western blot analyses (Supplementary Figs. 8, 10 and 11). 
Moreover, pathway analyses suggested that NONO-regulated genes 
were markedly enriched in Gene Ontology categories related to syn-
aptic functions (Supplementary Table 5).
To support this in silico prediction, we compared the synaptosomal 
transcriptomes from Nonogt and control mice. RNA was extracted 
from synaptosomal fractions obtained by density gradient ultra-
centrifugation24. The quality of this fractionation was confirmed by 
verifying enrichment of known synaptically transported RNAs and 
depletion of known nuclear RNAs relative to the whole transcriptome 
(Supplementary Fig. 10a–c) (GEO accession code GSE62573). We 
found that 30.5% of NONO-regulated transcripts were in fact synap-
tosomal, including Gabra2 (Supplementary Fig. 10d). This represents 
a significant over-representation compared to whole transcriptome 
(Supplementary Table 6, P = 0.0007; Supplementary Table 7). Hence, 
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Figure 2 Transcriptome analysis in human and mouse cells. (a) Heat map 
cluster analyses indicating similarity in expression profile among probes 
from the two patients and differences compared to the two controls.  
High detection signals relative to the mean are red, low detection  
signals are green. The cut-off for inclusion in the heat map was  
a 1.5-fold alteration of probe expression for both patients. Color scale 
ranges between –0.5 (green) and 0.5 (red). (b) Venn diagram showing 
the number of genes expressed in common or differentially expressed in 
the two patients compared to the mean of the two controls. Significant 
differences are based on a 1.5-fold difference and P < 0.05. U, up; D, 
down. (c) Hierarchical clustering analysis of combined mouse and human 
orthologous genes, resulting in a separation highlighting similarity of 
mouse and human transcriptional dysregulation. WT, wild type. Human 
samples are shown in orange and mouse samples are shown in green.
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Figure 3 Functional consequences of NONO deficiency in mice.  
(a) Side view of representative Nonogt mouse (right) compared to  
wild-type littermate (WT, left). (b) CT scan analysis indicating a flattened  
and distorted nose in Nonogt mice (right) compared to WT (left).  
(c) Box-and-whisker quantification of skull length, width and nose 
length in Nonogt mice (gray) compared to wild-type littermate (white) 
(center, meridian; box limit, quartiles 1 and 3; whiskers, minimum and 
maximum). n = 20 mice per genotype. ***P < 0.001; Student’s t-test.  
(d) MRI scan of representative Nonogt mouse (right) compared to wild-
type littermate (left). Arrows indicate cerebellum. Also see Supplementary 
Figure 5 and Supplementary Table 4. (e,f) Behavior of Nonogt mice 
and WT littermates in Morris water maze, n = 16–20 per genotype. 
Gray, Nonogt; white, WT. Bars represent means ± s.e.m. (e) Gallagher’s 
proximity test scores (average distance of mice from goal as fraction of 
total distance). Repeated ANOVA, gene P < 0.0237, time P < 0.001, 
interaction P = 0.9869. (f) Whishaw’s error (percentage of path outside  
an 18-cm-wide corridor connecting release point and goal). Gene  
P < 0.0215, time P < 0.001, interaction P = 0.7927.
np
g
© 
20
15
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
1734  VOLUME 18 | NUMBER 12 | DECEMBER 2015 nature neurOSCIenCe
a r t I C l e S
our data show that NONO plays a specific and important role in the 
regulation of synaptic RNAs.
Inhibitory synaptic structural defects in Nonogt mice
Gabra2 encodes a subunit of the GABAARs that potentiate 
most fast synaptic inhibition in the brain. Previous studies have 
demonstrated that GABAARs are anchored postsynaptically 
by gephyrin, which self-assembles into a scaffold and interacts 
with the cytoskeleton. The binding of gephyrin to GABAARs is 
mediated by interaction sites in the intracellular loop of GABAAR 
α1, α2 and α3 subunits25. We thus tested the consequences 
of loss of NONO at inhibitory synapses by immunohistologi-
cal studies of brain sections from wild-type and Nonogt mice, 
using antibodies directed against GABAAR α2 and gephyrin. 
Postsynaptic punctate staining for gephyrin and GABAAR α2 was 
significantly reduced in the CA3 hippocampal region of Nonogt mice 
(P = 0.0012), while staining of the presynaptic vesicular GABA transporter 
marker (vGAT) was unaffected (Fig. 4c). Quantitative evaluations 
showed that the number of gephyrin clusters was significantly 
reduced, but average cluster size was conserved (Fig. 4d). Western 
blot analyses showed markedly reduced GABAAR α2 levels in total 
brain lysates and synaptosomes (Supplementary Figs. 10 and 11). By 
contrast, gephyrin levels were similar in wild type and Nonogt in all 
compartments analyzed (Supplementary Fig. 11). Taken 
together, these data suggest that reduced GABAAR α2 levels in 
Nonogt mice are likely to be due to transcriptional deregulation. In 
turn, altered gephyrin clustering is likely to be a downstream 
consequence of altered synaptic composition because of these tran-
scriptional changes.
Synaptic defects in Nonogt mice probably have a cellular origin
In principle, the anomalies observed in Nonogt mice could 
arise from either cellular synaptic defects or broader neurodevel-
opmental changes. To distinguish between these possibilities and 
uncover potential cell-autonomous phenotypes, we used high-reso-
lution fluorescence in situ hybridization to analyze dissociated hip-
pocampal neurons from wild-type and Nonogt mice. As in intact brain 
slices, we observed a significant reduction of Gabra2 transcripts in 
NONO-deficient neurons (P = 0.0020), but unchanged transcript levels 
for the other postsynaptic markers collybistin (Arhgef9) and Gabra1 
(Supplementary Fig. 12). At the protein level, these cultures showed 
the same reduction of gephyrin scaffolding puncta and GABAAR α2 
levels (Fig. 4), demonstrating that primary culture neurons from these 
mice recapitulated the key cytological features observed in Nonogt 
mouse hippocampi. We therefore used this cellular model for func-
tional analysis of NONO in postsynaptic biology.
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Figure 4 Effects of NONO deficiency on  
synaptic biology. (a) Immunofluorescence 
labeling of NONO in wild-type (WT; top)  
and Nonogt (bottom) mouse coronal brain 
sections. PL, pyramidal cell layer; DG,  
dentate gyrus. Scale bars, 250 µm. (b) Scatter 
plot of hippocampal transcriptome from WT  
and Nonogt mice. Red, differentially  
expressed genes, P ≤ 0.01 and log ratio ≥ 0.5. 
Blue lines indicate twofold difference.  
(c) Immunohistochemical staining for  
inhibitory postsynaptic marker gephyrin  
(green), GABAAR α2 receptor (red) and the 
presynaptic marker vGAT (blue) in WT  
and Nonogt mice in the CA3 stratum radiatum  
of the hippocampus. Scale bars, 5 µm.  
(d) Left, scatter plot quantification of gephyrin 
and GABAR α2 relative to VGAT density.  
Right, frequency distribution of gephyrin cluster 
size. White circles, WT; black circles,  
Nonogt. (e–l) Immunofluorescence analysis of 
gephyrin postsynaptic clusters in vitro.  
(e–g) Primary hippocampal rat neurons 
expressing control GFP-gephyrin alone (e), 
coexpressed with myc-NONO (f) or  
coexpressed with RNA binding-deficient  
myc-NONO-RRM (g). Boxed region is  
magnified beneath. (h–j) Primary hippocampal 
rat neurons expressing control GFP-gephyrin  
alone (h), coexpressed with myc-NONO-RRM (i)  
or coexpressed with myc-NONO-RRM  
and GABAAR α2 (j). Scale bars, 10 µm.  
(k) Quantification of gephyrin cluster density  
in e–g by normal density distribution  
modeling, in 9 neurons from each of 3 
independent experiments. Control × NONO  
P = 0.001, control × myc-NONO-RRM P = 0.009 
using Kolmogorov-Smirnov test. (l) Identical 
curve-fit quantification of gephyrin clusters  
in h–j, showing complete rescue of the  
impaired gephyrin cluster distribution by GABAAR α2 overexpression. Control × NONO-RRM P = 0.009, control × NONO-RRM + GABAAR α2 P = 0.563, 
NONO-RRM × NONO-RRM + GABAAR α2 P = 0.014 using Kolmogorov-Smirnov test.
np
g
© 
20
15
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
nature neurOSCIenCe  VOLUME 18 | NUMBER 12 | DECEMBER 2015 1735
a r t I C l e S
1.8
* *
1.6
1.4
1.2
G
ep
hy
rin
/G
A
D
65
1.0
0.8
0.6
0.4
0.2
0
WT
AAV–
WT
AAV+
Nonogt
AAV–
Nonogt
AAV+
No
no
gt –
W
T+
W
T–
No
no
gt +
a b
c
DAPI AAV pHluorin GABAAR α2 Merge GFP Gephyrin GAD65
It has been previously established in cultured primary neurons that 
overexpression of green fluorescent protein-tagged gephyrin (GFP-
gephyrin) has no apparent effect on gephyrin clustering26. This tool 
was used to examine in more detail the effects of NONO on postsyn-
aptic structures. Conversely to what was observed in NONO-deficient 
mouse neurons, overexpression of myc-tagged NONO in wild-type 
primary hippocampal neurons expressing GFP-gephyrin caused a 
significant increase in density of GFP-gephyrin puncta compared to 
that in neurons transfected with GFP-gephyrin alone (P = 0.001). 
By contrast, a reduction in GFP-gephyrin density was observed in 
cells transfected with a construct overexpressing a mutant form of the 
NONO protein, myc-NONO RRM (Fig. 4e,f). This construct contains 
four point mutations in the RNA recognition motif (RRM) and is 
therefore unable to bind to single-stranded RNAs. Thus, we conclude 
that the function of NONO in synaptic biology depends upon the 
RNA-binding domain of this protein.
Rescue by re-expression of GABAARs at Nonogt synapses
Gephyrin depends on the presence of GABAARs to form postsyn-
aptic clusters in GABAergic synapses, and the size and density of 
gephyrin scaffolding can be correlated to strength and frequency of 
GABAergic transmission25,26. Gephyrin clustering is largely impaired 
in the mice lacking the GABAAR α2 subunit (Gabra2−/−)27. Therefore, 
we hypothesized that the altered gephyrin distribution observed in 
NONO-deficient neurons might in part be the consequence of Gabra2 
transcript deregulation.
If this hypothesis were true, then we might expect the morphologi-
cal defects observed in Nonogt neurons to be rescued by overexpress-
ing GABAAR α2. And indeed, transfection of plasmids expressing 
GABAAR α2 was able to rescue the reduced gephyrin cluster density 
observed in cultured neurons transfected with myc-NONO-RRM 
(Fig. 4g,h). Similarly, unilateral viral infection of hippocampal neu-
rons with adeno-associated viruses overexpressing GABAAR α2 
in vivo28 was also able to rescue the reduced cluster density in the 
infected hippocampus, while the contralateral uninfected side remains 
unaffected (Fig. 5). Both these observations support the view that 
alteration of GABAAR α2 levels is key to the etiology of the morpho-
logical defects observed in Nonogt neurons.
DISCUSSION
In this study, we have shown that NONO null mutations are the likely 
cause of a clinically recognizable intellectual disability syndrome. 
One of the three patients that we identified also harbors a deletion 
at 15q13.3, a locus at which copy number variation predisposes to 
epilepsy and intellectual disability29. While we cannot exclude a 
minor effect of the 15q13.3 deletion on the neurological presentation 
of patient MCCID1, its absence in the other two NONO-deficient 
patients argues that NONO null mutations result in the syndromic 
intellectual disability we document.
A mouse model deficient in NONO recapitulated the main features 
of this syndrome. Studying brains and neurons from these mutant 
mice suggested that NONO has an unsuspected function in regulating 
inhibitory synaptic biology, results also consistent with intellectual 
and anxiety phenotypes of these mice. Previous studies have identi-
fied NONO as a member of a neuronal RNA transport complex10 and 
demonstrated increased NONO abundance at synapses in response 
to synaptic activity30, but no study to our knowledge has yet linked 
dysfunction in NONO or other DBHS proteins to any human disease. 
Our studies clearly demonstrate that, in the brain, NONO actively reg-
ulates expression of synaptic transcripts on a global scale: one-third of 
all NONO-regulated transcripts are synaptic. These data point to an 
essential role of NONO in neuronal connectivity and raise the issue 
of the function of the two other DBHS proteins in this process.
Based upon such widespread regulation, the phenotypes observed in 
patients and mice are likely the collective result of many factors arising 
from NONO-mediated transcriptional defects. For example, we have 
previously shown that NONO is important to circadian clock control17, 
and circadian clock defects are observed in NONO-deficient mice20, 
as well as in patient and mouse fibroblasts. Various studies have shown 
that altering the circadian system affects learning and memory31, so 
local clock function may contribute to the phenotype observed in 
NONO-deficient neurons. Gene ontological enrichment suggested that 
many further aspects of synaptic function might also be affected.
Our morphological studies demonstrate that this defect in the regu-
lation of synaptic RNA metabolism ultimately regulates even dendritic 
spine morphology, as visualized by the scaffolding protein gephyrin. 
These defects in gephyrin scaffolding are mirrored by changes in the 
receptors that anchor it. The most abundant hippocampal GABAAR 
isoform, GABAAR α2, was downregulated in NONO-deficient cells 
and mice. Moreover, inhibitory synapse structural defects caused by 
NONO dysfunction were rescued by increasing the number of these 
receptors in both cells and mice. Thus, despite the broad transcriptional 
defects caused by NONO deficiency, our experiments highlight this 
receptor as a player in the etiology of NONO-related synaptic changes. 
At the moment, it is unknown whether GABAergic deficits might also 
be a central component of NONO-associated intellectual disability. 
Favoring such an idea, infusion of GABAAR α2/α3-specific inhibitors 
(TPA023, L-838417 and NS11394) has shown effects not only on affec-
tive behaviors but also on memory and ketamine-induced memory 
deficits32,33. Moreover, disruption of GABAAR α2 oligomerization 
Figure 5 GABA receptor overexpression rescues  
synaptic structural defects. (a) Fluorescence  
microscopy of hippocampal slices after unilateral  
stereotactic injection of AAV expressing pHluorin- 
tagged GABAAR α2. Scale bar, 500 µm.  
(b) Immunohistochemical staining for GFP (green,  
left), gephyrin (red, middle) and the presynaptic  
marker GAD65 (blue) in wild-type (rows 1 and 2)  
and Nonogt mice (rows 3 and 4) in the stratum  
radiatum of CA3 in the hippocampus in the absence (rows 1 and 3) or presence  
(rows 2 and 4) of AAV expressing pHluorin-tagged GABAAR α2. Scale bars, 20 µm. 
(c) Quantification of gephyrin relative to GAD65 density, which was unchanged  
across experimental conditions. Scatter plot shows data points for 4–7 mice;  
WT × Nonogt AAV−, P = 0.013; WT × Nonogt AAV+, P = 0.042; Student t-test.
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leads both to memory deficits and to changes in prepulse inhibition, 
a phenotype we observed in Nonogt mice34. Finally, in rats selected 
for low and high conditioned fear responses, such behavior correlates 
with levels of GABAAR α2 expression35. However, there is as yet no 
direct evidence linking the synaptic deficits we describe to the behav-
ioral changes in mutant animals, and so it is unclear whether targeting 
GABA transmission will have any therapeutic effect in patients.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Gene Expression Omnibus: GSE62571 and GSE62573.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
AcknowledgmenTS
We are grateful to the patients and their family members for their participation 
in our study and to the Functional Genomics Center Zürich (FGCZ) for 
transcriptomic services. This program has received a state subsidy managed by 
the National Research Agency under the Investments for the Future program 
bearing the reference ANR-10-IAHU-01.This study was also supported by the 
Centre National de la Recherche Scientifique (CNRS), the Fondation pour la 
Recherche Médicale (DEQ20120323702) and the Ministère de la Recherche 
et de l’Enseignement Supérieur, as well as by the Swiss National Science 
Foundation, the Zurich Clinical Research Priority Program “Sleep and Health,” 
the Zurich Fonds zur Förderung des akademischen Nachwuchses and the Zurich 
Neurozentrum (ZNZ). D.M., S.A.B. and S.K.T. are affiliates of the ZNZ Life 
Sciences Zurich graduate program, and S.A.B. is a member of the Zürich Center 
for Interdisciplinary Sleep Research (ZIS). The DDD study presents independent 
research commissioned by the Health Innovation Challenge Fund (grant number 
HICF-1009-003), a parallel funding partnership between the Wellcome Trust and 
the UK Department of Health, and the Wellcome Trust Sanger Institute (grant 
number WT098051). The views expressed in this publication are those of the 
author(s) and not necessarily those of the Wellcome Trust or the Department of 
Health. The research team acknowledges the support of the UK National Institute 
for Health Research, through the Comprehensive Clinical Research Network.
AUTHoR conTRIBUTIonS
L.C., S.A.B., J.-M.F. and S.K.T. designed the study. J.A., M. Rio and K.P. recruited and 
evaluated the study subjects. N.B. performed and analyzed the human brain imaging, 
and D.M., P.S., A.S. and M. Rudin performed and analyzed the mouse brain imaging. 
M.L. analyzed whole-exome sequencing data and performed transcriptional analysis 
and western blot analysis on patient cells, and L.G. performed circadian analyses 
on patient cells. S.M. contributed to whole-exome sequencing data analysis. C.B.-F. 
performed whole-exome sequencing. N.C. and P.N. performed the bioinformatics 
studies. R.H. and S.J.M. supplied engineered virus for in vivo rescue experiments. 
D.M. executed and analyzed all experiments on mouse tissues, and D.M. and M.Ž. 
executed and analyzed experiments in rodent cells. D.M., C.K., F.C., A.-K.F. and 
D.P.W. performed and analyzed mouse behavioral experiments. A.M. contributed 
to the clinical evaluation of the patients. K.S.-P. and O.A. contributed to the WES 
analysis. G.B. prepared cultured neurons for all experiments in this study. All authors 
contributed to writing and editing the manuscript. 
comPeTIng FInAncIAl InTeReSTS
The authors declare no competing financial interests.
Reprints and permissions information is available online at http://www.nature.com/
reprints/index.html.
1. Fox, A.H., Bond, C.S. & Lamond, A.I. P54nrb forms a heterodimer with PSP1 that 
localizes to paraspeckles in an RNA-dependent manner. Mol. Biol. Cell 16, 5304–
5315 (2005).
2. Myojin, R. et al. Expression and functional significance of mouse paraspeckle protein 
1 on spermatogenesis. Biol. Reprod. 71, 926–932 (2004).
3. Shav-Tal, Y. & Zipori, D. PSF and p54nrb/NonO – multi-functional nuclear proteins. 
FEBS Lett. 531, 109–114 (2002).
4. Dong, X., Sweet, J., Challis, J.R., Brown, T. & Lye, S.J. Transcriptional activity of 
androgen receptor is modulated by two RNA splicing factors, PSF and p54nrb. Mol. 
Cell. Biol. 27, 4863–4875 (2007).
5. Amelio, A.L. et al. A coactivator trap identifies NONO (p54nrb) as a component of the 
cAMP-signaling pathway. Proc. Natl. Acad. Sci. USA 104, 20314–20319 (2007).
6. Park, Y., Lee, J.M., Hwang, M.Y., Son, G.H. & Geum, D. NonO binds to the CpG 
island of oct4 promoter and functions as a transcriptional activator of oct4 gene 
expression. Mol. Cells 35, 61–69 (2013).
7. Kim, K.K., Kim, Y.C., Adelstein, R.S. & Kawamoto, S. Fox-3 and PSF interact to activate 
neural cell-specific alternative splicing. Nucleic Acids Res. 39, 3064–3078 (2011).
8. Patton, J.G., Porro, E.B., Galceran, J., Tempst, P. & Nadal-Ginard, B. Cloning and 
characterization of PSF, a novel pre-mRNA splicing factor. Genes Dev. 7, 393–406 
(1993).
9. Kaneko, S., Rozenblatt-Rosen, O., Meyerson, M. & Manley, J.L. The multifunctional 
protein p54nrb/PSF recruits the exonuclease XRN2 to facilitate pre-mRNA 3′ 
processing and transcription termination. Genes Dev. 21, 1779–1789 (2007).
10. Kanai, Y., Dohmae, N. & Hirokawa, N. Kinesin transports RNA: isolation and 
characterization of an RNA-transporting granule. Neuron 43, 513–525 (2004).
11. Izumi, H., McCloskey, A., Shinmyozu, K. & Ohno, M. p54nrb/NonO and PSF promote 
U snRNA nuclear export by accelerating its export complex assembly. Nucleic Acids 
Res. 42, 3998–4007 (2014).
12. Nakagawa, S. & Hirose, T. Paraspeckle nuclear bodies—useful uselessness? Cell. 
Mol. Life Sci. 69, 3027–3036 (2012).
13. Bond, C.S. & Fox, A.H. Paraspeckles: nuclear bodies built on long noncoding RNA. 
J. Cell Biol. 186, 637–644 (2009).
14. Chen, L.L., DeCerbo, J.N. & Carmichael, G.G. Alu element-mediated gene silencing. 
EMBO J. 27, 1694–1705 (2008).
15. Prasanth, K.V. et al. Regulating gene expression through RNA nuclear retention. 
Cell 123, 249–263 (2005).
16. Zhang, Z. & Carmichael, G.G. The fate of dsRNA in the nucleus: a p54nrb-containing 
complex mediates the nuclear retention of promiscuously A-to-I edited RNAs. 
Cell 106, 465–475 (2001).
17. Brown, S.A. et al. PERIOD1-associated proteins modulate the negative limb of the 
mammalian circadian oscillator. Science 308, 693–696 (2005).
18. Duong, H.A., Robles, M.S., Knutti, D. & Weitz, C.J. A molecular mechanism for 
circadian clock negative feedback. Science 332, 1436–1439 (2011).
19. Kowalska, E. et al. NONO couples the circadian clock to the cell cycle. Proc. Natl. 
Acad. Sci. USA 110, 1592–1599 (2013).
20. Kowalska, E. et al. Distinct roles of DBHS family members in the circadian 
transcriptional feedback loop. Mol. Cell. Biol. 32, 4585–4594 (2012).
21. de Ligt, J. et al. Diagnostic exome sequencing in persons with severe intellectual 
disability. N. Engl. J. Med. 367, 1921–1929 (2012).
22. Rauch, A. et al. Range of genetic mutations associated with severe non-syndromic 
sporadic intellectual disability: an exome sequencing study. Lancet 380, 
1674–1682 (2012).
23. Vissers, L.E., de Vries, B.B. & Veltman, J.A. Genomic microarrays in mental 
retardation: from copy number variation to gene, from research to diagnosis. 
J. Med. Genet. 47, 289–297 (2010).
24. Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic 
causes of developmental disorders. Nature 519, 223–228 (2015).
25. Tyagarajan, S.K. & Fritschy, J.M. Gephyrin: a master regulator of neuronal function? 
Nat. Rev. Neurosci. 15, 141–156 (2014).
26. Tyagarajan, S.K. et al. Regulation of GABAergic synapse formation and plasticity 
by GSK3β-dependent phosphorylation of gephyrin. Proc. Natl. Acad. Sci. USA 108, 
379–384 (2011).
27. Panzanelli, P. et al. Distinct mechanisms regulate GABAA receptor and gephyrin 
clustering at perisomatic and axo-axonic synapses on CA1 pyramidal cells. 
J. Physiol. (Lond.) 589, 4959–4980 (2011).
28. Jacob, T.C. et al. Gephyrin regulates the cell surface dynamics of synaptic GABAA 
receptors. J. Neurosci. 25, 10469–10478 (2005).
29. Mullen, S.A. et al. Copy number variants are frequent in genetic generalized epilepsy 
with intellectual disability. Neurology 81, 1507–1514 (2013).
30. Zhang, G., Neubert, T.A. & Jordan, B.A. RNA binding proteins accumulate 
at the postsynaptic density with synaptic activity. J. Neurosci. 32, 599–609 (2012).
31. Ruby, N.F. et al. Hippocampal-dependent learning requires a functional circadian 
system. Proc. Natl. Acad. Sci. USA 105, 15593–15598 (2008).
32. Castner, S.A. et al. Reversal of ketamine-induced working memory impairments by 
the GABAAalpha2/3 agonist TPA023. Biol. Psychiatry 67, 998–1001 (2010).
33. Hofmann, M. et al. Assessment of the effects of NS11394 and L-838417, alpha2/3 
subunit-selective GABA(A) [corrected] receptor-positive allosteric modulators, in tests for 
pain, anxiety, memory and motor function. Behav. Pharmacol. 23, 790–801 (2012).
34. Hines, R.M. et al. Disrupting the clustering of GABAA receptor α2 subunits in the 
frontal cortex leads to reduced gamma-power and cognitive deficits. Proc. Natl. 
Acad. Sci. USA 110, 16628–16633 (2013).
35. Lehner, M. et al. Differences in the density of GABA-A receptor alpha-2 subunits 
and gephyrin in brain structures of rats selected for low and high anxiety in basal 
and fear-stimulated conditions, in a model of contextual fear conditioning. Neurobiol. 
Learn. Mem. 94, 499–508 (2010).
np
g
© 
20
15
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
nature neurOSCIenCedoi:10.1038/nn.4169
ONLINE METHODS
Patients. All human protocols were reviewed and approved by the institutional 
review board of the Necker Hospital and informed consent was obtained from 
all subjects involved in this study. The study has UK Research Ethics Committee 
approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 
granted by the Republic of Ireland REC). Written consent was obtained to publish 
patient photographs.
MCCID1 was the second child of healthy, non-consanguineous parents. Family 
history is unremarkable. He was born in the 41st week of gestation, after a normal 
pregnancy and delivery and an Apgar score of 10/10. Parameters at birth were in the 
normal range (weight 3,370 g, LW 50.5 cm, HC 34 cm). Developmental milestones 
were delayed: he was able to walk alone at 3 years of age and had limited speech 
with preserved comprehension. He developed absence seizures at the age of 5 
years and continued to have seizures with increased frequency. He had strabismus 
and myopia. By the age of 15 years, he developed severe kyphoscoliosis. On exam-
ination at 17.5 years, his height was 1.79 m (+1 s.d.), his weight 50 kg (−1.5 s.d.) 
and OFC 60.5 cm (+4 s.d.). Hands and feet were narrow, with long fingers and 
toes, overriding toes and bilateral ankylosis of the metacarpophalangeal joint 
of the thumb. He had flat feet with dystrophic nails. He had a long and expres-
sionless face, malar hypoplasia, short palpebral fissures, small and open mouth 
with drooling, high-arched-palate and enamel defect. He had a slender build and 
distal amyotrophy. Speech was limited, with simple sentences, severe elocution 
disability and nasal speech. Extensive metabolic screening was normal. Myotonic 
dystrophy and fragile X were excluded. Brain MRI demonstrated bilateral mega-
lencephaly, a thick corpus callosum, enlarged white matter, septum pellucidum 
cyst and a small cerebellum. High resolution cytogenetic studies (array CGH) 
identified a de novo 15q13.3 deletion.
MCCID2, a male, is the first child of healthy, non-consanguineous parents 
with no medical family history of note. He has three healthy younger sisters 
(Fig. 1a). Because hydramnios and short long bones were noted in the second 
trimester of pregnancy, amniocentesis was performed and karyotyping showed 
normal chromosomes, 46,XY. He was born at 37.6 weeks gestation with low birth 
parameters (weight 2,540 g, BL 46 cm, OFC 35.5 cm) and an Apgar score of 10/10. 
He presented poor suckling, gastrointestinal reflux, stridor, cryptorchidism and 
hypotonia from birth. He developed convergent strabismus within the first year 
of age. Motor skills have been delayed, with head control achieved at 10 months 
and walking unaided at 3 years of age. At that time language was limited to a few 
single words. He was of slender build and macrocephalic, with weight and height 
−2 s.d. and head circumference +2 s.d. His thorax was long and narrow and he 
developed kyphoscoliosis and pes planus. He was awkward and slow, with weak 
patellar reflexes. He suffered from drooling, persistent swallowing difficulties 
and severe elocution disability with nasal speech. He could not blow or smack. 
He had multiple dental caries due to mouth breathing. Chronic otitis media 
resulted in conductive hearing loss of 40 to 60 dB and has been treated with 
grommets. Hands and feet were narrow, with overriding toes and ankylosis of 
the metacarpophalangeal joint of both thumbs. Although macrocephalic, his 
forehead was relatively short and narrow with low frontal and temporal hairline. 
The face was elongated, with upslanting palpebral features, a convergent squint, 
a thin and high nasal root with deviated nasal septum and large tip with short 
columella, severe malar hypoplasia, a small open mouth with narrow and high 
palate, narrow dental arcades and crowding of teeth. Ears were normally placed 
and folded, with hypoplastic ear lobes. He made constant progress, was toilet 
trained at about 7 years, speaks in sentences and is able to write his name and 
read simple words. He has a shy, gentle and cheerful behavior. When last seen at 
15 years of age, puberty was delayed and orthopedic surgery for the kyphosco-
liosis was planned. Brain MRI performed at 18 months and 8 years showed a 
thick corpus callosum, asymmetric trigone and lateral ventricles and a Chiari 
malformation type I (Fig. 1b). EEG showed no gross anomaly. Extensive meta-
bolic screening was normal. Skeletal X-rays showed no malformation of the 
vertebrae. CytoChip (BlueGnome, Cambridge) array-CGH did not detect any 
copy number variation.
whole-exome sequencing. Agilent SureSelect libraries were prepared from 
3 µg of genomic DNA sheared with a Covaris S2 Ultrasonicator as recommended 
by the manufacturer. Exome capture was performed with the 50 Mb SureSelect 
Human All Exon kit (Agilent Technologies) using a multiplex approach with 
molecular barcodes for traceable identification of samples. Sequencing was carried 
with the SOLiD5500 (Life Technologies) on a pool of barcoded exome libraries. 
75 + 35 paired-end reads were generated and mapped on the human genome 
reference (NCBI build37/hg19 version) using LifeScope (Life Technologies).
For each subject, sequences produced allowed a mean sequence coverage 
between 42–87 reads per bp.  The average coverage was 70×, with more than 
75% of targeted bases covered 15×. Sequence reads were aligned to the human 
reference genome sequence (assembly GRCh37) using Mapreads. SNPs and indels 
were called using Genome Analysis Toolkit and Picard Tools. Poorly mapped (less 
than 3× cover) and low-quality reads (quality score less than 20) were removed. 
In-house software (PolyWeb) was used to annotate and filter the variants.
mice. Generation of Nonogt mice was described previously20. Mice have been back-
crossed more than 12 generations to C57/Bl6J. All experiments were performed by 
comparing adult wild-type and mutant littermates (2–3 months old). Procedures 
were approved by the veterinary authorities of the Canton of Zürich.
cT and mR scanning and analysis. The skulls of 20 mice per genotype were 
scanned with in vivo 3D micro computed tomography (Quantum Fx, PerkinElmer, 
Waltham, MA). All mice were sacrificed before scanning and placed in the micro 
CT in ventral recumbency with the head centered in the field of view. Scans were 
taken with an isotropic voxel resolution of 59 µm. The protocol used 90 kV and 
100 µA with 50 ms per projection, resulting in a total scan time of 3 min for 
360°. 3D surface reconstructions of all skulls were created using the Quantum 
Fx viewer and assessed or scored for signs of deformation and morphological 
anomalies by two independent investigators. Analysis of skull parameters was 
done as described previously36. Micro MR images were acquired as described pre-
viously37 via high-resolution MRI of the mouse brain at 9.4 T using a cryogenic 
quadrature transceiver coil (in-plane image resolution 60 × 60 mm2).
mouse behavioral experiments. Statistical models. Data were analyzed using 
mixed ANOVA models with genotype (KO, WT) as between-subjects factor. 
Within-subject factors were added as needed to explore the dependence of 
genotype effects on place, time or stimulus. Significant interactions and, where 
necessary, significant main effects were further explored by Tukey-Kramer post 
hoc tests or by splitting the ANOVA model, as appropriate. One-sample t-tests 
were used for follow-up comparisons against chance levels. Variables known to 
produce strongly skewed distributions and/or frequent outliers were subjected 
to a log transformation before ANOVA analysis (as indicated, for example, for 
latency measures). The significance threshold was set at 0.05. The false discovery 
rate (FDR) control procedure of Hochberg was applied to groups of conceptually 
related variables within single tests to correct significance thresholds for multiple 
comparisons.
Prepulse inhibition. The session consisted of a series of six 40-ms startling 
pulses of different intensities varying between 100 and 120 dB to get an average 
magnitude of the initial animal’s startle response. The animal was then subjected 
to a succession of six discrete trials. Each trial included a short period of back-
ground white noise (control no-stimulus condition), followed by 20-ms prepulses 
(4, 8, 12, 16 and 20 dB above the background white noise) and 40-ms startling 
pulses (100 to 120 dB) presented either separately or in combination (prepulse + 
pulse, with a delay of 100 ms between the two stimuli). The session was completed 
with six more 40-ms startling pulses and background noise. The time interval 
between two stimulus presentations varied between 10 and 20 s.
Elevated plus maze. The apparatus was a crossbar-shape maze, comprising two 
symmetrically arranged open arms equipped with 3-mm ledges and two closed 
arms equipped with 20-cm walls. The intersection of the four arms formed a 
small central zone (5 cm × 5 cm). The maze was elevated 38 cm from the ground. 
The whole apparatus was made of semi-transparent Plexiglas. The mouse was 
put on the central platform, the head facing a closed arm. The session lasted 
5 min, starting once it entered all four paws into one of the arms. The behavioral 
parameters were recorded online.
Open-field test. The large open-field arena was circular, with a diameter of 150 cm, 
a white plastic floor and 35-cm-high sidewalls made of white polypropylene. 
Illumination was by indirect diffuse room light (four 40-W bulbs, 12 lx). Each 
subject was released near the wall and observed for 10 min. The same proce-
dure was repeated the next day, resulting in a total observation time of 20 min. 
Movements were tracked using Noldus EthoVision. The number of deposited 
fecal boli was recorded after each session.
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Light-dark box. A 20 × 30 cm lit chamber with transparent Perspex walls 
(20 cm high) and open top was connected to a 20 × 15 × 20 cm polyvinylchloride 
box. The box was dark (~10 lx) and completely enclosed, except for the 7.5 × 7.5 cm 
opening connecting it to the lit chamber. The lit chamber was under direct room 
light (~450 lx). Each subject was released in the middle of the lit compartment and 
observed for 5 min. Movements were tracked using Noldus EthoVision. Rearings 
and grooming were recorded using the keyboard event-recorder provided by the 
video-tracking system.
Morris water maze. This test was conducted as described previously38, in ~12-lx 
light in a 150-cm-diameter water pool. Six trials were conducted per day, each 
separated by 30–60 min and lasting 2 min: either learning (15 × 15 cm platform 
0.5 cm above the water surface) or testing (platform 0.5 cm below water surface). 
Three days of acquisition and 2 d of reversal training were conducted. Movements 
were tracked using Noldus Ethovision. Mouse performance was evaluated using 
Gallagher’s measure of proximity (the average distance from the goal during 
the test) and Whishaw’s error (percentage of path outside a 18-cm wide straight 
corridor connecting release point and goal)39,40.
expression analyses. Total cultured human and mouse skin fibroblast RNAs 
were isolated using the RNeasy Mini Kit (Qiagen). RNA quality was assessed 
using RNA Nano LabChips and the 2100 Bioanalyzer (Agilent Technologies) 
and RNA concentration was measured by spectrophotometry (Nanodrop, 
Thermo Scientific). Briefly, 100 ng of total RNA was reverse transcribed, and 
second-strand DNA was produced and amplified by in vitro transcription in the 
presence of biotinylated ribonucleotides using the IVT Express kit (Affymetrix). 
Microarray experiments were performed for two controls and two patients in 
duplicate on Affymetrix Human PrimeView Arrays (a genome-wide array with 
49,293 probe sets) hybridized with fragmented amplified RNA as recommended 
by the manufacturer. Similarly, mouse RNAs from two Nonogt and two wild-type 
mice were hybridized on Affymetrix GeneChip Mouse Genome 430 2.0 Arrays 
(a genome wide array allowing the analysis of 39,000 transcripts). Fluorescence 
data were imported into two analysis software packages: Affymetrix Expression 
Console and R Bioconductor. Gene expression levels were calculated using the 
RMA algorithm Expression Console and flags were computed using a custom 
algorithm in R (http://www.r-project.org/). Assuming that a maximum of 80% 
of genes are expressed, we selected the 20% lowest values for each microarray 
to be background expression data measures. We then computed a threshold at 
2 s.d. over the mean of the background. All probes whose normalized intensity 
measures were lower than the computed threshold were flagged 0 instead of 1. 
The list has been created filtering probes flagged as 1 for at least half of the chips. 
The group comparisons were done using Student’s t test. We filtered the result-
ing P values at 5% and used no correction. Cluster analysis was performed by 
hierarchical clustering using the Spearman correlation similarity measure and 
average linkage algorithm.
Meta-analysis of human and mouse samples types was performed as previ-
ously described41.
Mouse hippocampal RNAs were extracted using a GenElute Mammalian Total 
RNA Miniprep Kit (Sigma, St. Louis, MO, USA) according to the manufacturer’s 
instructions. Total RNA was quantified by absorbance spectroscopy and 
RNA integrity and quality were assessed by 1.0% agarose gel electrophoresis. 
Total RNA (1 µg) was transcribed to cDNA with SuperScript II (Invitrogen, 
Carlsbad, CA, USA) using random hexamer primers according to the manu-
facturer’s instructions.
For quantitative real-time PCR (qPCR), we used 20 ng of cDNA, and sin-
gle transcript levels of genes were detected with the HOT FIREPol EvaGreen 
qPCR Mix (Solis BioDyne, Tartu, Estonia) and an AB7900 thermocycler. 
Primers used for detection of synaptic transcripts were as follows: Actb (β-actin), 
AGTGTGACGTTGACATCCGTA (sense), GCCAGAGCAGTAATCTCCTTCT 
(antisense); Gphn, GGCGACCGAGGGAATGAT (sense), CCACCCAACAAA 
GAAGGATCTT (antisense); Gabra1, GGTTGACCGTGAGAGCTGAA (sense), 
CTACAACCACTGAACGGGCT (antisense); Gabra2, CAGTGGCCCATAACA 
TGACAAT (sense), GGACATTCGGCTTGGACTGT (antisense); Camk2a, 
CCCCTTTCGCCTACATGTGA (sense), GGCTACAGTGGAGCGGCTTA 
(antisense). Data were analyzed using the comparative CT method42.
For transcriptome analysis using RNA-seq, the quality of the isolated RNA 
was determined with a Qubit (1.0) Fluorometer (Life Technologies, California, 
USA) and a Bioanalyzer 2100 (Agilent, Waldbronn, Germany). RNAs were then 
processed using the TruSeq Stranded mRNA Sample Prep Kit (Illumina, Inc., 
California, USA) according to the manufacturer recommendations. The TruSeq 
SR Cluster Kit v3-cBot-HS or TruSeq PE Cluster Kit v3-cBot-HS (Illumina, Inc., 
California, USA) was used for cluster generation using 8 pM of pooled normal-
ized libraries on the cBOT. Sequencing was performed on a Illumina HiSeq 2000 
system using the TruSeq SBS Kit v3-HS (Illumina, Inc., California, USA) with 
paired-end 2 × 100 reads or single-end 1 × 100 reads.
RNA-seq reads were quality-checked with fastqc, which computes various 
quality metrics for the raw reads. Reads were aligned to the genome and tran-
scriptome with TopHat v. 1.3.3. Before mapping, the low-quality ends of the reads 
were clipped (three bases from the read start and ten bases from the read end). 
TopHat was run with default options. The fragment length parameter was set to 
100 bases with a s.d. of 100 bases. The distribution of the reads across genomic 
features was assessed on the basis of these alignments. Isoform expression was 
quantified with the RSEM algorithm43 with the option for estimation of the read 
start position distribution turned on.
cell culture and transfection. Human primary fibroblasts were cultured at 
37 °C under 5% CO2 in RPMI + Glutamax or OPTI-MEM + Glutamax sup-
plemented with 10% FBS and 5% penicillin/streptomycin (complete medium) 
(Life Technologies).
Mouse primary hippocampal neuron cultures were prepared as described 
previously44. Hippocampal cultures were transfected with 0.5 µg of either 
eGFP–gephyrin construct or the specific myc–NONO construct according to the 
protocol described previously44. Cells were transfected after 8 DIV and processed 
for immunofluorescence 7 d later. In cotransfection experiments, the total DNA 
concentration was maintained at 1.5 µg.
Plasmids used for transfection. The eGFP–gephyrin P1 variant has been 
described previously45. Overexpression of myc-NONO and myc-NONO RRM 
were conducted using the plasmids described previously46. The GABRA2 con-
struct was created amplifying rat cDNA with primers containing HindIII and 
XhoI sites and subsequent cloning into the pCR3.1 vector.
western blot. Human primary fibroblasts protein extracts were prepared on 
ice in lysis buffer (50 mM Tris pH 8, 170 mM NaCl, 0.5% NP-40 X-100, 50 mM 
NaF and complete EDTA-free protease inhibitor 11697498001, Roche Applied 
Science). The Bradford protein assay was used to determine the concentration 
of each sample (B6916-500 Sigma). 20–30 µg of protein extracts were separated 
by 4–20% SDS-PAGE (SDS-PAGE Mini-Protean TGX Stain Free, no. 4568093, 
Bio-Rad). Stain-free gels were exposed to UV light for 2.5 min before trans-
fer to 0.2-µm nitrocellulose membranes (Trans-Blot Turbo Transfer Pack, no. 
1704158, Bio-Rad). UV-induced fluorescence corresponding to total proteins 
was first visualized with ChemiDoc MP imaging system, then the membranes 
were blocked with 5% nonfat dried milk powder (Invitrogen) diluted in PBS-T 
(PBS with 0.2% Tween-20) for 1–2 h and incubated overnight at 4 °C in 2% milk 
in PBS-T with the primary antibodies: NONO, SFPQ, PSPC1 and β-actin, the 
last of these used as a control for protein loading. Membranes were then incu-
bated with horseradish peroxidase–conjugated secondary antibodies. Proteins 
were visualized using ECL-Plus (GE Healthcare). Various exposure times were 
performed for either autoradiography films and AGFA development (Curix 60 no. 
1829) or Chemidoc system (Bio-Rad). Raw signal intensities were first obtained 
for target proteins as well as total proteins profile, with the same sample as refer-
ence, using volume tools in the ImageLab software (Bio-Rad). Background signal 
was deducted from each value. Final quantification data were given as a ratio of 
target signal to total signal.
Mouse brain lysate and sample preparation were performed as described47. 
Each lane was loaded with 50 µg protein and, after blotting, the nitrocellulose 
membrane was directly blocked for 30 min with a 1% solution of Western 
Blocking Reagent (Roche Applied Science, Indianapolis, IN, USA).
Antibodies. The following antibodies were used: mouse anti-β-actin (AM4302, 
1:20,000; Ambion), rabbit anti-NONO (LS-C31127, 1:2,000; LSBio Cliniscience), 
rabbit anti-SFPQ (A301-320A, Bethyl), mouse anti-PSPC1 (sc-374181, 1:1,000; 
Santa Cruz), mouse anti-gephyrin (mAb7a, 1:3,000; or 3B11, 1:10,000; Synaptic 
Systems, Gottingen, Germany), rabbit anti-vGAT antibody (1:3,000, Synaptic 
Systems, Gottingen, Germany), guinea pig anti-GABAAR α2 subunit17, mouse 
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anti-myc (1:10,000, Roche), rabbit anti-NONO (1:500)20, rabbit anti-PSPC1 
(1:500)20, rabbit anti-SFPQ (1:500)20, NeuN (MAB377, Millipore), GFAP (Z0334, 
DAKO and MAB360, Millipore), PSD-95 (MA1-045, Affinity Bioreagents), 
β-actin (MAB1501, Millipore). Secondary antibodies were donkey anti-rabbit 
IgG-HRP antibody (1:20,000; sc-2313, Santa Cruz) or donkey anti-mouse 
IgG-HRP antibody (1:20,000; sc-2314, Santa Cruz).
Immunocytochemistry and imaging of human skin fibroblasts. Cells were 
harvested and seeded 1 d before immunocytochemistry experiment with equal 
cell density for each well. 24 h later, cells were rinsed twice in PBS and fixed in IC 
fixation buffer (FB001, Invitrogen) for 10 min at room temperature. Cells were 
then permeabilized with 0.5% Triton X-100 for 10 min at room temperature. After 
three PBS washes, blocking was done with 5% BSA diluted in 0.1% Triton-PBS 
for 30 min at room temperature. Hybridization was performed with the first 
antibodies used in western blotting experiments in a moist chamber overnight 
at 4 °C. After three 10-min 0.1% Triton-PBS washes, detections were carried 
out with secondary antibodies Alexa488 anti-rabbit IgG (1:400, A-11034, Life 
Technologies) and Alexa594 anti-mouse IgG (1:400, A-11005, Life Technologies) 
for 1 h at room temperature in a dark and moist chamber. After three 10-min 
0.1% Triton-PBS washes and a final PBS wash, slides were mounted with ProLong 
(P36935, Invitrogen). Images were taken with a Zeiss LSM700 microscope fitted 
with a Plan-Apochromat 40×/1.3 oil DIC M27 objective and Zen 2009 software. 
Images montage was done using ImageJ.
Immunocytochemistry and immunohistochemistry on mouse samples. 
Immunocytochemistry was performed as described previously26. In short, cells 
were rinsed in PBS and fixed for 10 min in 4% paraformaldehyde at room temper-
ature. Cells were permeabilized with 0.01% Triton X-100 and detection of intra-
cellular proteins were achieved by incubation for 60 min at room temperature 
with primary antibodies diluted in PBS containing 10% normal serum, followed 
by incubation with secondary antibodies coupled to Cy3 or Cy5 (1:500, Jackson 
ImmunoResearch) for 30 min at room temperature. Finally, coverslips were 
mounted with fluorescent mounting medium (Dako Cytomation, Carpinteria, 
CA). The GABAAR α2 subunit antibody was incubated with living cultures for 
90 min in culture medium48.
Staining and immunohistochemical analysis of synaptic components was 
performed as previously described. Briefly, mice were anesthetized with pento-
barbital and perfused intracardially with ice-cold, oxygenated ACSF. The brain 
was extracted and cut in blocks containing the regions of interest for analysis (for 
example, hippocampal formation). The tissue was plunged into ice-cold, freshly 
prepared fixative (4% PFA in PBS) and postfixed for 90 min, rinsed with PBS, 
cryoprotected overnight in 30% sucrose in PBS, frozen with powdered dry ice and 
stored at −80 °C. Sections were cut from frozen blocks with a sliding microtome at 
a thickness of 40 µm and were collected free-floating in PBS. They were incubated 
under continuous agitation in primary solution (Tris buffer, pH 7.4, containing 
0.2% Triton X-100, 2% normal serum and the primary antibodies) for 15–48 h 
at 4 °C, washed in Tris buffer and incubated for 30–60 min at room temperature 
in secondary antibodies coupled to a fluorochrome.
Immunofluorescence images were captured by laser scanning confocal micro-
scopy, using a 20×, 40× or 64× lens (NA 1.4, 1,024 × 1,024 pixels, Zeiss LSM 710). 
Final illustrations were prepared from the maximal intensity projection of stacks 
of images spaced at 0.5 µm. Signals were quantified using a custom macro created 
with ImageJ software. Images were background-subtracted and filtered with a 
Gaussian filter, but no change in brightness and contrast was applied.
High-resolution in situ hybridization. Dissociated hippocampal neurons were 
prepared and maintained as previously described49. In situ hybridization was per-
formed using the QuantiGene (QG) ViewRNA kit from Panomics as previously 
described with the following modifications. Cells (DIV 14) were incubated for 
2 min at room temperature in PBS and fixed for 15 min using 4% formaldehyde 
solution (in PBS, pH 7.4). After fixation, cells were permeabilized using a deter-
gent solution (Panomics) for 5 min. Cells were washed three times with PBS fol-
lowed by in situ hybridization using Gabra2 and pan-collybistin (Arhgef9) probes 
designed by Panomics, following the manufacturer’s instructions. Briefly, probes 
were diluted 1:100 in hybridization buffer supplied by Panomics, incubated at 
40 °C (3 h), washed, hybridized with preamplification oligonucleotides (1:100) 
at 40 °C (40 min), washed, hybridized with amplification oligonucleotides (1:100) 
at 40 °C (40 min), washed and, finally, hybridized with label oligonucleotides 
(1:100) at 40 °C (40 min). Coverslips were dried at room temperature in a verti-
cal position. Coverslips were mounted with Dako-DAPI fluorescent mounting 
Medium (Dako S3023) and left to polymerize overnight at 4 °C.
Synaptosome preparation. Synaptosomes were prepared as described previ-
ously50. In brief, mouse brains were homogenized in 5 ml homogenization buffer 
(0.32 M sucrose, 1 mM EDTA pH 7.4, 1 mM dithiothreitol, phenylmethylsulfo-
nyl fluoride solution (Sigma, 93482-50ML-F), complete mini-protease inhibitor 
(Roche Diagnostics) for 10 s using a Polytron. The homogenate was centrifuged 
at 1,000g for 10 min at 4 °C, yielding the nuclear fraction and the supernatant. The 
supernatant was centrifuged at 31,000g for 5 min at 4 °C using a discontinuous 
Percoll gradient. The layer between the 3% and 10% Percoll was collected, washed 
in 30 ml of homogenization buffer and further centrifuged at 22,000g for 15 min 
at 4 °C. The pellet was resuspended in EBC buffer (50 mM Tris-HCl pH 8.0, 
120 mM NaCl and 0.5% NP-40) containing complete mini-protease inhibitor 
(Roche Diagnostics) and phosphatase inhibitor cocktail 1 and 2 (Sigma-Aldrich) 
for western blot analysis or lysis buffer for RNA extraction (GenElute Mammalian 
Total RNA Miniprep Kit, Sigma).
Stereotactic intrahippocampal injections. Adult male mice (8–20 weeks) weigh-
ing >25 g were anesthetized with 5% isoflurane in oxygen during head fixation 
and trepanation; subsequently, isoflurane concentration was reduced to 1.5%. 
1 µl of AAV9 encoding pHluorin-tagged GABRA2 (ref. 28) was injected uni-
laterally into CA3 of the hippocampus under stereotaxic guidance (coordinates 
from bregma: antero-posterior −2.0 mm; medio-lateral 2.3 mm; dorso-ventral 
2.4 mm from the skull). During the operation and recovery, mice were held on 
a warm pad. For recovery, the mice were housed singly until behavior returned 
to normal.
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